Kiniksa Pharmaceuticals International PLC
KNSA
Company Profile
Business description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Contact
105 Piccadilly
Second Floor
LondonW1J 7NJ
GBRT: +44 7814319100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
366
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.30 | 34.80 | -0.40% |
| CAC 40 | 7,807.87 | 162.01 | -2.03% |
| DAX 40 | 22,839.56 | 662.69 | -2.82% |
| Dow JONES (US) | 46,021.43 | 203.72 | -0.44% |
| FTSE 100 | 10,079.73 | 16.23 | 0.16% |
| HKSE | 25,274.40 | 226.18 | -0.89% |
| NASDAQ | 22,090.69 | 61.73 | -0.28% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,989.99 | 61.62 | -0.47% |
| S&P 500 | 6,606.49 | 18.21 | -0.27% |
| S&P/ASX 200 | 8,428.40 | 43.90 | -0.52% |
| SSE Composite Index | 3,957.05 | 49.50 | -1.24% |